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that	 combined	 pARser81	 and	 pARser213	 reduces	 survival	 and	 would	 benefit	 from	 dual-targeting	27	
androgen-dependent	and	Akt-driven	disease.			28	





expression	 increased.	 Castrate-resistance	 pARser81	 expression	was	 not	 associated	with	 survival	 but	34	
high	pARser213	expression	was	associated	with	reduced	survival	from	relapse.	Combined	high	pARser81	35	
and	pARser213	was	associated	with	reduced	survival	from	relapse.	pARser81	expression	was	induced	by	36	
10nM	 DHT	 or	 10nM	 EGF	 and	 pARser213	 expression	 was	 induced	 by	 treatment	 with	 10nM	 EGF	 in	37	
LNCaP-AI	 cells.	 Cell	 viability	was	 reduced	 following	 treatment	with	 10nM	Enzalutamide	 and	10nM	38	
BKM120.	 8	 genes	 were	 differentially	 expressed	 between	 hormone-naïve	 and	 castrate-resistant	39	
tumours	and	25	genes	were	differentially	expressed	between	castrate-resistant	 tumours	with	high	40	
and	low	pARser213	expression.		41	
Conclusion:	 Combined	 pARser81	 and	 pARser213	 provides	 a	 novel	 prognostic	 biomarker	 for	 castrate-42	





Prostate	 cancer	 (CaP)	 accounts	 for	 over	 47	 000	 new	 UK	 diagnoses	 each	 year	 (1).	 The	47	
androgen	 receptor	 (AR)	 plays	 vital	 roles	 in	 CaP;	 therefore,	 current	 therapies	 aim	 to	 inhibit	 AR	48	




AR	 phosphorylation,	 including	 serine	 81	 and	 308	 are	 linked	 to	 AR	 nuclear-cytoplasmic	53	
shuttling	and	CaP	progression	(3).		Serine	81	is	the	most	common	AR	phosphorylated	site	(pARser81)	54	
and	 associates	 with	 AR	 transcriptional	 activity.	 In	 the	 presence	 of	 androgens,	 pARser81	 occurs	 by	55	
cyclin-dependent	 kinases	 (CDKs),	 such	 as	 CDK1	 and	 9,	which	 sensitize	 AR	 to	 low	 levels	 of	 adrenal	56	
androgens	(4).		However,	in	the	absence	of	androgens,	pARser81	may	occur	by	alternative	kinases	and	57	
reactivate	AR	signalling.	58	
Recently,	 androgen-independent	 AR	 activation	 has	 been	 proposed	 as	 a	 mechanism	 for	59	
castrate-resistance.	 Phosphatidylinositol	 3-OH	 kinase	 (PI3K)/Akt	 signaling	 associates	 with	60	
phosphorylated	 AR	 serine	 213	 (pARser213),	 resulting	 in	 AR	 stability	 (5).	 We	 have	 previously	61	
demonstrated	 in	 vitro	 upregulation	 of	 PI3K/Akt	 signalling	 at	 castrate-resistance	 and	 increased	62	
pARser213	 expression.	 Furthermore,	 we	 demonstrated	 an	 increase	 in	 pARser213	 expression	 in	 the	63	
transition	 from	 hormone-naïve	 to	 CRPC,	 this	 increase	 was	 also	 associated	 with	 decreased	 cancer	64	
specific	 survival	 from	relapse	 (6).	However,	no	mechanistic	analysis	or	analysis	of	differential	gene	65	
expression	 profiles	 were	 conducted	 for	 the	 differing	 roles	 of	 AR	 phosphorylation	 at	 the	 different	66	
sites.		67	
Epidermal	growth	factor	receptor	(EGFR)	associates	with	PI3K/Akt	activation	and	CRPC.	We	68	
previously	 reported	 that	 EGFR	 variant	 III	 (EGFRvIII),	 a	 constitutively	 activated	 form	 of	 EGFR,	69	
associates	with	 CRPC.	 EGFRvIII	 activates	 PI3K/Akt	 signalling,	with	 EGFRvIII	 and	 loss	 of	 PTEN	 being	70	
prevalent	 in	 CaP,	 suggesting	 an	 androgen-independent	 mechanism	 for	 pARser81	 and	 pARser213	71	
expression	 (6,	 7).	 However,	 despite	 no	 causative	 relationship	 observed	 between	 EGFRvIII	 and	72	
pARser81,	 EGFRvIII	 expression	 reduces	 CDK	 inhibitors	 and	 activates	 the	 cell	 cycle.	 As	 pARser81	73	





Therefore,	 this	 study	 aimed	 to	 determine	 the	 use	 of	 pARser81	 and	 pARser213	 as	 prognostic	79	












performed	 peptide	 competitive	 assays	 to	 confirm	 the	 specificity	 of	 pARser81	 phosphorylation	 site	91	
using	the	peptide	with	the	protein	sequence	QQQQQQET(pS)PRQQ	raised	in	a	rabbit	(EZbiolab	Inc,	92	
USA)	at	1:1	and	incubated	with	the	pARser81	antibody	(#07-1375;	Merk	Millipore,	USA)	overnight	at	4°	93	
before	 performing	 immunohistochemistry	 as	 below.	 Additionally,	McCall	et	 al	 performed	western	94	
blots	 for	 pARser213	 (#IMG-561;	 Imgenex,	 USA)	 (also	 termed	 pARser210)	 to	 determine	 antibody	95	
specificity.	 This	 was	 followed	 by	 confirming	 that	 the	 pARser213	 antibody	 only	 detected	 the	96	
phosphorylated	 protein	 by	 destroying	 phosphorylated	 proteins	 with	 calf	 intestinal	 alkaline	97	






Immunofluorescence	 was	 performed	 as	 described	 (10).	 pARser81	 and	 pARser213	 antibodies	 were	104	
incubated	overnight	at	4°C	at	1:1000	and	1:200	respectively	and	visualised	using	the	Zeiss	LSM	780	105	
Confocal	 (Zeiss,	Germany).	 	 Pixel	 intensity	was	 quantified	 using	 ImageJ,	with	 10	 images	 taken	per	106	











Patients	 were	 selected	 based	 on	 their	 response	 to	 hormone	 treatment	 (sub-capsular	 bilateral	118	
orchidectomy	 or	 LHRH	 agonists	 combined	 with	 antiandrogens)	 and	 their	 relapse	 (2	 rises	 in	 PSA	119	
>10%).	 HN	 tissue	 was	 obtained	 via	 trans-rectal	 ultrasound	 guided	 biopsies	 and	 CR	 tissue	 was	120	




(#07-1375;	Merk	Millipore,	USA)	antibody	was	 incubated	overnight	 at	4°C,	 at	1:4000	and	pARser213	125	
(#IMG-561;	 Imgenex,	 USA)	 was	 incubated	 for	 1	 hour	 at	 room	 temperature	 at	 1:100.	 A	 negative	126	
control	was	included	with	the	absence	of	the	primary	antibody.	Slides	were	scanned	and	visualised	127	
using	Hamamatsu	NanoZoomer	(Welwyn	Garden	City,	UK)	and	Slidepath	Digital	Image	Hub,	version	128	









1mM	EDTA)	 under	 pressure	 for	 5	minutes.	 pARser81	 (#07-1375;	Merk	Millipore,	 USA)	 and	 pARser213	138	
(#IMG-561;	 Imgenex,	 USA)	 antibodies	were	 incubated	 together	 overnight	 at	 4°C,	 diluted	 at	 1:100	139	
and	1:600	respectively.	Staining	was	captured	using	the	Zeiss	LSM	780	Confocal,	visualised	using	Carl	140	
Zeiss	 ZEN	 2	 blue	 edition	 software	 (Zeiss,	 Germany),	 and	 categorised	 based	 on	 absence	 and/	 or	141	
presence	of	phosphorylated	AR	antibodies.		142	
Statistical	Analysis		143	
Statistical	 analysis	was	performed	using	 SPSS	 version	22.	 Interclass	 correlation	 coefficients	 (ICCCs)	144	
confirmed	 weighted	 histoscores	 were	 consistent	 between	 2	 independent	 observers.	 Receiver	145	
operator	 characteristic	 (ROC)	 curves	 identify	 threshold	 for	 low/high	 expression.	 	 Combined	146	
expression	 of	 pARser81	 and	 pARser213	 was	 coded	 as;	 low	 pARser81	 and	 pARser213	 the	 both	 low	 group,	147	
either	high	pARser81	or	pARser213	the	one	high	group,	and	both	high	pARser81	and	pARser213	the	both	high	148	
group.	Time	to	biochemical	relapse	(BR),	cancer-specific	survival	from	diagnosis	(CSSD)	and	relapse	149	
(CSSR)	was	analysed	using	Kaplan	Meier	 log-rank	analysis	 followed	by	Cox	 regression,	Chi-squared	150	
analysis,	and	Wilcoxon	signed-rank	test.			151	
TempO-Seq	Gene	Differential	Expression	152	
TempO-Seq	 gene	 expression	 profiling	 was	 performed	 according	 to	 manufacturer’s	 directions	 (17	153	











Clinico-pathological	 data	was	 collected	 from	 109	 patients	 with	matched	 hormone-naïve	 (HN)	 and	164	
castrate-resistant	 (CR)	 tumour	 pairs	 and	 included	 age	 at	 diagnosis	 (mean	 69,	 Interquartile	 Range	165	
(IQR)	66-74),	Gleason	grade	at	diagnosis	(mean	7,	IQR	6-9),	Gleason	grade	at	relapse	(mean	8.55,	IQR	166	
8-9),	 serum	PSA	concentration	at	diagnosis	 (mean	146.51	ng/ml,	 IQR	8.55-126.18),	and	serum	PSA	167	
concentration	at	 relapse	 (mean	62.95	ng/ml,	 IQR	4.57-39.50).	All	patients	had	biochemical	 relapse	168	







that	 separated	 pARser81	 expression	 into	 high	 and	 low.	HN	pARser81	 expression	 at	 diagnosis	was	 not	176	
associated	 with	 time	 to	 biochemical	 relapse,	 CSS	 (p=0.630	 and	 p=0.933	 respectively)	 or	 clinico-177	
pathological	 features.	 Following	 the	 development	 of	 CR	 disease,	 pARser81	 expression	 decreased	178	
(p=0.002)	(Figure	1A	and	B).	CR	nuclear	pARser81	expression	ranged	from	0-200	WHU	with	a	median	179	
of	 90	WHU	 ((IQR	 50-120).	 ROC	 curve	 analysis	 determined	 a	 threshold	 of	 95	WHU	 that	 separated	180	
pARser81	 expression	 into	 high	 and	 low.	 Despite	 this,	 46.7%	 of	 CR	 samples	 expressed	 high	 pARser81	181	
expression.	 However,	 CR	 pARser81	 expression	 was	 not	 associated	 with	 CSSR	 (p=0.068)	 (Figure	 1C).	182	






increased	 in	 66.3%	 of	 patients	 (p=0.002),	 with	 high	 expression	 associating	 with	 reduced	 CSSR	189	
(p=0.001,	HR=2.457	(1.388-4.349))	(Figure	1D,	E,	and	F).	High	CR	pARser213	expression	stratified	mean	190	
CSSR	from	4.44	years	 in	 low	expressing	tumours	to	2.54	years	 in	high	expressing	tumours	and	was	191	




High	 CR	 pARser81	 and	 high	 pARser213	 expression	 reduced	 CSSR	 from	 5.73	 years	 to	 2.03	 years	196	
(p=000297)	(Figure	2A).	Furthermore,	5-year	survival	was	reduced	from	47%	for	patients	expressing	197	









and	 4	 hours	 (p<0.001	 and	 p<0.001	 respectively)	 (Figure	 4B,	 D,	 E	 and	 F).	 	 Subsequently,	 we	207	
determined	 the	 effects	 on	 AR	 phosphorylation	 by	 blocking	 androgen-dependent	 by	 the	 non-208	
steroidal	second-generation	AR	antagonist	Enzalutamide	or	PI3K-driven	phosphorylation	by	the	pan-209	
class	PI3K	 inhibitor	BKM120.	10nM	Enzalutamide	significantly	 reduced	10nM	DHT	 induced	pARser81	210	
expression	and	interestingly	reduced	pARser213	expression	to	unstimulated	levels	(Figure	5A,	B	and	C).	211	
Additionally,	 10nM	 BKM120	 significantly	 reduced	 10nM	 EGF	 induced	 pARser81	 and	 pARser213	212	
expression	 (Figure	 5D,	 E	 and	 F).	 Unfortunately,	 when	 used	 as	 monotherapies,	 neither	 10nM	213	




Differential	 gene	 expression	 analysis	 on	 2723	 genes,	 pre-selected	 for	 their	 biological	 relevance	 in	218	
cancer,	was	performed	on	10	patients	with	matched	HN	and	CR	tumour	samples.	In	CR	tumours,	8	219	
genes	 were	 differentially	 expressed	 (DE)	 when	 compared	 to	 their	 matched	 HN	 tumour	 including	220	





high	 pARser213	 expression	 had	 25	 genes	 DE	 including	 18	 downregulated	 and	 7	 upregulated	 when	226	
compare	to	low	pARser213	expressing	CR	tumours	(p<0.001).	DE	genes	with	the	lowest	p-values	were	227	
GSTP1,	CAMK2B,	ATF5,	UQCRFS1,	 and	C1R.	The	 top	3	upregulated	genes	with	 the	 largest	absolute	228	
log2foldchange	 are	 implicated	 in	 CaP	 including	 CAMK2B	 (p=6.44x10-5,	 log2FC=2.367,	 lfcSE=0.605)	229	
involved	 in	 aldosterone	 synthesis,	 HPN	 (TMPRSS1)	 (p=0.00035,	 log2FC=1.938,	 lfcSE=0.542)	 which	230	
promotes	CaP	metastasis,	and	AMACR	(p=0.00045,	log2FC=2.213,	lfcSE=0.631)	which	is	expressed	in	231	
CaP	(Supplementary	table	3).	However,	MAOA	(p=0.00117,	log2FC=-2.073,	lfcSE=0.639),	involved	in	232	
epithelial	 to	 mesenchymal	 transition,	 was	 the	 only	 one	 gene	 DE	 in	 high	 versus	 low	 CR	 pARser81	233	





Despite	 the	 development	 of	 new	 hormonal	 therapies	 to	 treat	 advanced	 CaP,	 such	 as	238	
Abiraterone	(Johnson	&	Johnson)	and	MDV3100	(Medivation),	in	the	majority	of	advanced	CaPs	only	239	
temporary	disease	control	 is	achieved	with	androgen-independent	 reactivation	of	AR	commencing	240	
2-3	 years	 after	 ADT.	 Therefore,	 this	 traditional	 etiology	 of	 androgen-driven	 disease	 needs	 to	 be	241	
revised	 and	 the	 elucidation	 of	 molecular	 mechanisms	 involved	 in	 CRPC	 is	 required.	 It	 has	 been	242	
hypothesised	 that	 various	 pathways	 lead	 to	 CaP	 recurrence	 in	 hormone-deprived	 environments.	243	
However,	 with	 the	 lack	 of	 predictive	 markers	 to	 identify	 activated	 pathways,	 inappropriate	244	
treatments	 are	 administered,	 clinical	 trials	 fail,	 and	 patient	 survival	 is	 not	 improving	 despite	245	
increases	in	new	therapeutic	options.		246	
PI3K	 activation	 due	 to	 the	 loss	 of	 the	 tumor	 suppressor	 gene,	 PTEN,	 highlights	 a	 genetic	247	
abnormality	that	induces	androgen-independent	AR	expression	in	40-70%	of	patients	(16,	17)	.	Akt,	a	248	
downstream	member	 of	 PI3K,	 plays	 vital	 roles	 in	 cancer	 growth	 and	migration	 and	 increases	 AR	249	
transcriptional	activity	 in	 vitro	 identifying	pARser213	 in	 response	 to	Akt	binding	 (18).	 Interestingly,	 it	250	
has	previously	been	identified	that	high	pARser213	expression	in	this	cohort	is	associated	with	elevated	251	
pAKTser473	at	castrate-resistance	(6).	An	additional	link	between	Akt	activity	and	survival	during	ADT	252	
has	 been	 identified,	 therefore	 promoting	 CRPC	 development	 (19).	 Furthermore,	 AR	 nuclear	253	
exportation	 is	 influenced	by	pARser650	by	MAPK	 signalling,	 therefore	highlighting	 contributions	 that	254	
signal-transduction	 cascades	 play	 in	 CaP	 (4).	 However,	 in	 vitro	 studies	 using	 Akt	 specific	 and	 PI3K	255	
specific	 inhibitors	 show	 differing	 results	 with	 both	 reduced	 and	 increased	 AR	 expression	 being	256	




their	 matched	 HN	 tumour	 with	 the	majority	 involved	 in	 the	 cell	 cycle	 including	 CDK1	 (M-phase),	261	




expression	 by	 10nM	 DHT	 and	 subsequently	 inhibited	 expression	 following	 10nM	 Enzalutamide	266	
treatment.	However,	no	effect	of	cell	viability	was	observed.		267	
High	 CR	 pARser213	 expression	 associated	 with	 reduced	 CSSR	 by	 1.9	 years	 (p=0.001)	 and	268	
suggests	that	following	ADT	the	AR	is	reactivated	androgen-independently.	However,	contradictory	269	
to	our	findings	of	decreased	survival,	it	has	been	reported	that	pARser213	in	response	to	Akt	can	lead	270	
to	 ligand	 dissociation	 and	 degradation	 of	 AR	 (26).	 Furthermore,	 pARser213	 in	 response	 to	 Mdm2	271	
results	 in	 ubiquitination	 and	 degradation	 of	 AR	 and	 its	 splice	 variant	 AR-V7	 (27).	 Following	272	
transcriptomic	analysis,	multiple	genes	were	dysregulated	 in	high	CR	pARser213	expressing	 tumours.	273	
However,	 due	 to	 lack	 of	 numbers	 unadjusted	 p-values	 were	 assessed	 due	 to	 their	 biological	274	
relevance.	HPN,	which	codes	for	hepsin,	 is	overexpressed	 in	up	to	90%	of	CaPs	often	>10-fold	(28,	275	
29).	We	observed	almost	a	2-fold	increase	in	HPN	in	high	CR	pARser213	expressing	tumours	and	not	in	276	
high	 pARser81	 expressing	 tumours.	 Furthermore,	HPN	 correlates	with	 high	Gleason	 grade	 and	 poor	277	
clinical	 outcome	 (30,	 31).	 Additionally,	 GSTP1	 was	 underrepresented	 in	 high	 pARser213	 expressing	278	
tumours,	 a	 gene	 involved	 in	 reducing	 oxidative	 damage.	 However,	 when	 silenced	 GSTP1	 can	279	
promote	CaP	initiation	in	90-95%	of	CaPs	suggesting	pARser213	represents	an	aggressive	phenotype.		280	
ErbB	 family	 receptors	 are	 involved	 in	 CaP	 tumourigenesis	 and	 progression,	 with	 aberrant	281	
associations	 observed	 during	 the	 development	 of	 CR	 disease	 and	 loss	 of	 androgen	 signaling	 (3).	282	
HER2	 overexpression	 has	 been	 reported	 in	 CaP	 progression	 much	 like	 breast	 cancer,	 another	283	
hormone	sensitive/refractory	disease	(32).	HER2	inhibitors	have	shown	to	reduce	recurrence	by	up	284	
to	50%	 in	HER2	positive	breast	cancers,	with	 the	hope	of	HER	specific	 inhibitors	similarly	 reducing	285	
CaP	 progression	 (33,	 34).	 However,	 overexpression	 of	 EGFR	 is	 not	 associated	 with	 CaP	 initiation,	286	
differentiation,	 or	 positive	 margins	 but	 with	 progression	 and	 castrate-resistance	 (35-37).	287	
Interestingly,	 as	 a	 result	 of	 EGFRvIII	 expression	 and	 subsequent	 activation	 of	 PI3K/Akt,	 increased	288	
proliferation	and	cell	cycle	progression	has	been	observed.	This	signalling	reduces	the	levels	of	the	289	
cyclin-dependent	 kinase	 inhibitor,	 p27KIP1,	 a	 known	 inhibitor	 of	 the	 transition	 from	G1	 to	 S	 phase	290	
within	the	cell	cycle	in	glioblastoma	(38).	Interestingly,	EGFRvIII	associates	with	reduced	expression	291	
of	 CDK	 inhibitors	 and	 is	 hypothesised	 to	 result	 in	 elevated	 CDK	 expression	 and	 ultimately	292	
overexpression	of	pARser81.	Following	10nM	EGF	stimulation,	we	observed	a	significant	 induction	of	293	
pARser81	an	pARser213	expression,	further	adding	to	weight	to	a	potential	mechanism	in	which	pARser81	294	




at	 relapse	 they	 had	 a	 reduced	 CSSR	 of	 3.71	 years	 (p=0.000297).	 This	 significantly	 increased	 the	299	
prognostic	power	of	these	markers	when	compared	alone	to	patient	survival	(pARser81	p=0.068,	and	300	
pARser213	p=0.001).	 Furthermore,	patients	expressing	pARser81	 and	pARser213	within	 the	 same	cell	 via	301	
immunofluorescence	resulted	in	a	reduced	CSSR	of	3.57	years	(p=0.00011).	302	
Due	 to	 a	 feedback	 loop	 observed	 between	 AR	 and	 PI3K/AKT	 cascade,	 the	 use	 of	 anti-303	
androgens	and	PI3K	inhibitors	as	monotherapies	have	lacked	efficacy	with	no	significant	reduction	in	304	
cell	viability	observed	 in	LNCaP-AI	cells	 following	10nM	Enzalutamide	or	10nM	BKM120	(Figure	5G	305	
and	H).	 However,	when	 targeting	 both	 androgen-depenedent	 and	 PI3K-driven	AR	 activation	 using	306	
10nM	 enzalutamide	 and	 10nM	 BKM120,	 cell	 viability	 signifincatly	 reduced	 in	 LNCaO-AI	 cells.	307	
Therefore,	we	have	hypothesise	that	patients	expressing	pARser81	and	pARser213	expression	within	the	308	
same	cell	would	benefit	from	this	dual	therpauetic	approach	and	improve	the	efficacy	of	the	clinical	309	
trial	 by	Armstrong	et	al	 (8).	However,	 LNCaP	AI	 cells	harbour	multiple	mutations	 including	T878A,	310	
F876L,	and	F877L	within	the	ligand	binding	domain	portion	of	the	AR,	resulting	in	a	broader	ligand-311	




To	 conclude,	 further	 elucidation	 of	 these	 biomarkers	 are	 required	 to	 determine	 their	316	
localisation/co-localisation	 and	 whether	 combining	 pARser81	 and	 pARser213	 will	 provide	 any	 further	317	
understanding	 and/	 or	 prognostic	 power.	 In	 addition,	 the	 use	 of	 various	 drug	 combinations	 with	318	
anti-androgens	 such	as	Enzaultamide	and	PI3K/Akt	 inhibitors	 such	BKM120	on	patients	depending	319	

























































































































prostate	 cancer.	 (A)	 High	 and	 low	 pARser81	 expression	 in	 prostate	 cancer	 (B)	 pARser81	 expression	440	
significantly	 reduces	 following	 the	 development	 of	 castrate-resistant	 disease	 (C)	 High	 pARser81	441	
expression	 does	 not	 significantly	 reduce	 cancer	 specific	 survival	 from	 relapse	 (D)	 High	 and	 low	442	
pARser213	 expression	 in	 prostate	 cancer	 (E)	 pARser213	 expression	 significantly	 increases	 following	 the	443	
development	of	castrate-resistant	disease	(F)	High	pARser213	 	expression	significantly	reduced	cancer	444	
specific	survival	from	relapse.	Wilcoxon	signed-rank	tests	and	Kaplan	Meier	survival	curves	with	log-445	




Figure	 2:	 Combined	 pARser81	 and	 pARser213	 expression	 in	 castrate-resistant	 tumours.	 (A)	 Following	450	
immunohistochemistry,	 castrate-resistant	 patients	with	 high	 pARser81	 and	 high	 pARser213	 expression	451	
had	 significantly	 reduced	 cancer	 specific	 survival	 from	 relapse	 (B)	 Following	 dual	452	
immunofluorescence,	 castrate-resistant	 patients	 expressing	 pARser81	 and	 pARser213	 within	 the	 same	453	
cell	had	a	significantly	reduced	cancer	specific	survival	from	relapse	(C)	Example	of	castrate-resistant	454	
tumours	expressing	only	pARser81,	only	pARser213,	and	combined	pARser81	an	pARser213	within	the	same	455	
cell.	Kaplan	Meier	 survival	 curves	with	 log-rank	 tests	were	considered	significant	 if	P<0.05.	Censor	456	







expression	by	 8	 hours	 but	 not	 pARser213	 expression	 (E	 and	 F)	Quantification	of	AR	phosphorylation	464	
pixel	 intensity	 following	1	and	12	hour	10	nM	DHT	stimulation.	 	Each	experiment	was	repeated	to	465	
N=3.	DAPI	was	included	as	a	nuclear	stain	and	scale	bars	represent	50	µm.	Fluorescence	expression	466	
was	 quantified	 and	 compared	 to	 a	 control	 containing	 no	 primary	 antibody.	 Error	 bars	 represent	467	






Exposure	 to	 10	 nM	 EGF	 over	 1	 hour	 significantly	 increased	 pARser81	 expression	 by	 5	minutes	 and	473	
pARser213	 expression	 by	 30	minutes	 (C	 and	 D)	 Exposure	 to	 10	 nM	 EGF	 over	 12	 hours	 significantly	474	
increased	pARser81	expression	by	2	hours	and	pARser213	expression	by	4	hours	(E	and	F)	Quantification	475	
of	 AR	 phosphorylation	 pixel	 intensity	 following	 1	 and	 12	 hour	 10	 nM	 EGF	 stimulation.	 	 Each	476	
experiment	was	repeated	to	N=3.	DAPI	was	included	as	a	nuclear	stain	and	scale	bars	represent	50	477	
µm.	 Fluorescence	 expression	 was	 quantified	 and	 compared	 to	 a	 control	 containing	 no	 primary	478	
antibody.	Error	bars	represent	standard	error	and	statistical	analysis	was	performed	using	a	one-way	479	








expression	 (G)	 No	 effect	 on	 LNCaP-AI	 cell	 viability	 was	 observed	 following	 10	 nM	 Enzalutamide	487	
treatment	 over	 10	 days	 (H)	 No	 effect	 on	 LNCaP-AI	 cell	 viability	 was	 observed	 following	 10	 nM	488	
BKM120	 treatment	 over	 10	 days	 (I)	 Combined	 treatment	 with	 10	 nM	 Enzalutamide	 and	 10	 nM	489	
BKM120	significantly	reduced	LNCaP-AI	cell	viability	by	10	days.	 	Each	experiment	was	repeated	to	490	
N=3.	DAPI	was	included	as	a	nuclear	stain	and	scale	bars	represent	50	µm.	Fluorescence	expression	491	
was	 quantified	 and	 compared	 to	 a	 control	 containing	 no	 primary	 antibody.	 Error	 bars	 represent	492	
standard	 error	 and	 statistical	 analysis	 was	 performed	 using	 a	 one-way	 ANOVA	 with	 Bonferroni	493	






















































Gene	 Log2FoldChange	 lfcSE	 P-Value	 Adjusted	P-Value	
KIF11_3588	 1.606687	 0.324044	 7.11E-07	 0.002094	
HIST1H3B_12576	1.717355	 0.391572	 1.16E-05	 0.017011	
UGT1A10_28864	2.229366	 0.539585	 3.60E-05	 0.022069	
TYMS_21327	 1.304365	 0.318614	 4.24E-05	 0.022069	
CDKN3_17690	 1.660734	 0.406628	 4.42E-05	 0.022069	
CDK1_1196	 2.053808	 0.503347	 4.50E-05	 0.022069	
HMMR_3040	 1.194755	 0.300411	 6.98E-05	 0.029344	
CENPW_1256	 1.040229	 0.268995	 0.00011	 0.04053	
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Supplementary	 table	 3:	 Differential	 gene	 expression	 analysis	 between	 high	 and	 low	 pARser213	508	
expression	 in	 castrate-resistant	 tumours.	 25	 genes	 were	 differentially	 expressed	 in	 high	 pARser213	509	
expressing	 castrate-resistant	 tumours	 when	 compared	 to	 low	 pARser213.	 18	 genes	 were	510	
downregulated	and	7	genes	were	upregulated.	P>0.001	was	considered	significant	for	unadjusted	p-511	
values.	512	
Gene	 Log2foldchange	 LfcSE	 P-Value	 Adjusted	P-Value	
GSTP1_24644	 -2.3134	 0.578919	 6.44E-05	 0.04741	
CAMK2B_26957	 2.36701	 0.60481	 9.09E-05	 0.04741	
ATF5_501	 1.34956	 0.346107	 9.65E-05	 0.04741	
UQCRFS1_7566	 0.86679	 0.23363	 0.00021	 0.06063	
C1R_871	 -1.3565	 0.369807	 0.00024	 0.06063	
CASP1_26966	 -1.384	 0.38356	 0.00031	 0.06063	
HPN_25853	 1.93783	 0.541716	 0.00035	 0.06063	
KRT15_19413	 -3.248	 0.910927	 0.00036	 0.06063	
ARHGAP8_26848	 1.34436	 0.37758	 0.00037	 0.06063	
AMACR_14170	 2.21333	 0.630683	 0.00045	 0.0662	
LOC100510495_28176	-1.3128	 0.379924	 0.00055	 0.06728	
MYLK_4414	 -1.9181	 0.555136	 0.00055	 0.06728	
C3_886	 -1.9042	 0.554412	 0.00059	 0.06728	
SMAD3_27880	 -0.9936	 0.292956	 0.0007	 0.06982	
ID1_14943	 -1.8632	 0.550338	 0.00071	 0.06982	
IGFBP6_26498	 -1.8047	 0.542909	 0.00089	 0.07082	
CFH_27007	 -1.4165	 0.426346	 0.00089	 0.07082	
FGF2_2405	 -1.661	 0.500727	 0.00091	 0.07082	
CCND1_1062	 -0.7696	 0.232679	 0.00094	 0.07082	
HPN_3091	 1.86637	 0.565271	 0.00096	 0.07082	
SCARB1_6117	 1.08261	 0.333161	 0.00116	 0.08114	
FLNA_25912	 -1.4413	 0.448573	 0.00131	 0.0817	
BMP4_737	 -1.2925	 0.403309	 0.00135	 0.0817	
ZEB2_23804	 -1.1773	 0.367524	 0.00136	 0.0817	
TPSB2_17547	 -1.5698	 0.490942	 0.00139	 0.0817	
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